{"id":"NCT00097708","sponsor":"Jazz Pharmaceuticals","briefTitle":"Experimental Medication For the Treatment of Generalized Anxiety Disorder","officialTitle":"A Double-Blind, Placebo Controlled Trial of an Experimental Medication For the Treatment of Generalized Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-11","primaryCompletion":null,"completion":"2005-12","firstPosted":"2004-11-30","resultsPosted":"2014-10-03","lastUpdate":"2014-10-03"},"enrollment":511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"experimental anti-anxiety drug","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of Generalized Anxiety Disorder.","primaryOutcome":{"measure":"Change in HAM-A Total Score","timeFrame":"Baseline to week 8","effectByArm":[{"arm":"OROS Alprazolam","deltaMin":-12.9,"sd":null},{"arm":"IR Alprazolam","deltaMin":-15.7,"sd":null},{"arm":"Placebo","deltaMin":-12.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.6540"},{"comp":"OG001 vs OG002","p":"0.0005"},{"comp":"OG000 vs OG001","p":"0.0015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":171},"commonTop":["Somnolence","Headache","Fatigue","Dizziness","Nausea"]}}